ATE247507T1 - Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina - Google Patents

Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina

Info

Publication number
ATE247507T1
ATE247507T1 AT01918208T AT01918208T ATE247507T1 AT E247507 T1 ATE247507 T1 AT E247507T1 AT 01918208 T AT01918208 T AT 01918208T AT 01918208 T AT01918208 T AT 01918208T AT E247507 T1 ATE247507 T1 AT E247507T1
Authority
AT
Austria
Prior art keywords
compounds
outer retina
retina diseases
treat outer
ht1a activity
Prior art date
Application number
AT01918208T
Other languages
English (en)
Inventor
Robert J Collier Jr
Michael A Kapin
Mark R Hellberg
Thomas R Dean
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ATE247507T1 publication Critical patent/ATE247507T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT01918208T 2000-03-17 2001-02-23 Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina ATE247507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
PCT/US2001/005700 WO2001070222A2 (en) 2000-03-17 2001-02-23 Compounds with 5-ht1a activity useful for treating disorders of the outer retina

Publications (1)

Publication Number Publication Date
ATE247507T1 true ATE247507T1 (de) 2003-09-15

Family

ID=22700682

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01918208T ATE247507T1 (de) 2000-03-17 2001-02-23 Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina

Country Status (18)

Country Link
EP (3) EP1263434A1 (de)
JP (5) JP2003527423A (de)
KR (3) KR20030016239A (de)
CN (2) CN1418100A (de)
AR (1) AR028258A1 (de)
AT (1) ATE247507T1 (de)
AU (5) AU2001238552A1 (de)
BR (3) BR0109193A (de)
CA (3) CA2400637A1 (de)
DE (1) DE60100625T2 (de)
DK (1) DK1263504T3 (de)
ES (1) ES2204848T3 (de)
MX (3) MXPA02009071A (de)
PL (1) PL203709B1 (de)
PT (1) PT1263504E (de)
TW (1) TWI268777B (de)
WO (3) WO2001070223A1 (de)
ZA (1) ZA200206350B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
MXPA02009071A (es) * 2000-03-17 2003-05-23 Alcon Inc Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma..
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
EP1581209A4 (de) 2002-12-13 2009-03-11 Alcon Inc Neue benzopyran-analoga und ihre verwendung zur behandlung von glaukom
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP1792629A4 (de) 2004-08-25 2010-08-25 Takeda Pharmaceutical Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
EP2727585A1 (de) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo Screening-Methode
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2216023A4 (de) 2007-11-15 2013-03-13 Takeda Pharmaceutical Kondensiertes pyridinderivat und seine verwendung
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
EP3421030A1 (de) 2009-11-09 2019-01-02 Allergan, Inc. Zusammensetzungen und verfahren zur stimulation des haarwuchses
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
CA2901280A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
JP7770673B2 (ja) 2019-02-27 2025-11-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのアゼピノ－インドール及び他の複素環化合物
AU2022416279A1 (en) 2021-12-15 2024-07-25 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
PL4452267T3 (pl) * 2021-12-23 2025-06-23 Cilcare Dev Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (de) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
AU4249297A (en) * 1996-10-31 1998-05-22 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
MXPA02009071A (es) * 2000-03-17 2003-05-23 Alcon Inc Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma..

Also Published As

Publication number Publication date
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
ZA200206350B (en) 2003-08-08
EP1267878A2 (de) 2003-01-02
JP2003527423A (ja) 2003-09-16
MXPA02009071A (es) 2003-05-23
KR20030009390A (ko) 2003-01-29
CN1418100A (zh) 2003-05-14
DE60100625T2 (de) 2004-02-26
WO2001070230A3 (en) 2002-04-25
MXPA02009073A (es) 2003-03-12
WO2001070223A1 (en) 2001-09-27
JP2003527427A (ja) 2003-09-16
BR0109193A (pt) 2003-05-27
CN1418121A (zh) 2003-05-14
JP2003527422A (ja) 2003-09-16
CA2400639C (en) 2011-08-16
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
TWI268777B (en) 2006-12-21
AR028258A1 (es) 2003-04-30
EP1263504B1 (de) 2003-08-20
WO2001070230A2 (en) 2001-09-27
AU2005202600B2 (en) 2008-07-31
CA2399985A1 (en) 2001-09-27
AU2001239836A1 (en) 2001-10-03
WO2001070222A2 (en) 2001-09-27
KR20030016239A (ko) 2003-02-26
EP1263504A2 (de) 2002-12-11
BR0109230A (pt) 2003-06-03
JP4789231B2 (ja) 2011-10-12
HK1051504A1 (en) 2003-08-08
AU4531001A (en) 2001-10-03
KR100749191B1 (ko) 2007-08-13
PT1263504E (pt) 2003-12-31
JP2011153158A (ja) 2011-08-11
JP2011037901A (ja) 2011-02-24
MXPA02009072A (es) 2003-03-12
CA2400637A1 (en) 2001-09-27
CA2400639A1 (en) 2001-09-27
CN1198605C (zh) 2005-04-27
PL203709B1 (pl) 2009-11-30
WO2001070222A3 (en) 2002-07-25
EP1263434A1 (de) 2002-12-11
DK1263504T3 (da) 2003-12-08
ES2204848T3 (es) 2004-05-01
DE60100625D1 (de) 2003-09-25
PL358306A1 (en) 2004-08-09
KR20020082885A (ko) 2002-10-31

Similar Documents

Publication Publication Date Title
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60028863D1 (de) Elektrochirurgisches Handstück zur Behandlung von Gewebe
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
DE60027290D1 (de) Skleraprothese zur behandlung der weitsichtigkeit und anderer augenkrankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE60127552D1 (de) Intrakorporelle medikamente zur hoch-energetischen phototherapeutischen behandlung von krankheiten
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE400277T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE345123T1 (de) Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
ATE326969T1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1263504

Country of ref document: EP